IPILIMUMAB + SINTILIMAB + Cetuximab + DABRAFENIB for spinocerebellar degenerations

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 1 Mar 2026: Trial started, NCT07506109
  2. 1 Apr 2026: Trial registered, NCT07506109

The trials

NCT07506109: A Phase II Study of Sintilimab Combined With Ipilimumab N01, Cetuximab and Dabrafenib in Patients With Microsatellite-Stable, BRAF V600E-Mutated Metastatic Colorectal Cancer

State
Under way
Phase
Phase 2
People
49 planned
Started
1 Mar 2026
Primary completion
Dec 2027
Arms
First-line cohort, Second-line cohort
Results
None posted
  1. 1 Mar 2026: Trial started
  2. 1 Apr 2026: Trial registered

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.